Login to Your Account



New Standard of Care? Abraxane Wins Nod in Pancreatic Cancer

By Jennifer Boggs
Managing Editor

Monday, September 9, 2013

The FDA approved Celgene Corp.’s Abraxane Friday for use in pancreatic adenocarcinoma. It’s the first drug approved for patients with metastatic pancreatic cancer in nearly eight years, and analysts are expecting the combination of the albumin-bound version of paclitaxel and gemcitabine to become the new standard of care in what has remained an intractable disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription